GI
NTLA icon

GAMMA Investing’s Intellia Therapeutics NTLA Stock Holding History

GAMMA Investing’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$25.6K Buy
2,122
+651
+44% +$8.14K ﹤0.01% 2786
2026
Q2 		$24.9K Sell
1,471
-208
-12% -$2.91K ﹤0.01% 2719
2026
Q1 		$21.5K Buy
1,679
+1,261
+302% +$16.1K ﹤0.01% 2676
2025
Q4 		$3.76K Sell
418
-124
-23% -$1.71K ﹤0.01% 3395
2025
Q3 		$9.36K Buy
542
+196
+57% +$2.41K ﹤0.01% 2911
2025
Q2 		$3.25K Sell
346
-715
-67% -$5.87K ﹤0.01% 3268
2025
Q1 		$7.54K Buy
1,061
+695
+190% +$7.02K ﹤0.01% 2882
2024
Q4 		$4.27K Buy
366
+149
+69% +$2.33K ﹤0.01% 2983
2024
Q3 		$4.46K Sell
217
-2,428
-92% -$56K ﹤0.01% 2789
2024
Q2 		$59.2K Buy
2,645
+2,459
+1,322% +$58.5K 0.01% 1078
2024
Q1 		$5.12K Buy
186
+63
+51% +$1.75K ﹤0.01% 2401
2023
Q4 		$2.93K Buy
+123
New +$3.54K ﹤0.01% 2451

Other funds holding NTLA

VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing's NTLA Position: Q3 2026 in Review

GAMMA Investing increased its Intellia Therapeutics (NTLA) stake by 44% in Q3 2026, buying an estimated $8.14K and bringing the position to 2,122 shares worth $25.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2786.

GAMMA Investing first reported a position in NTLA in Q4 2023 and has held it in 12 quarters since. The position peaked at $59.2K in Q2 2024. 6 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • GAMMA Investing held 2,122 shares of Intellia Therapeutics worth $25.6K as of Q3 2026.
  • GAMMA Investing bought 651 Intellia Therapeutics shares in Q3 2026, an estimated $8.14K.
  • Intellia Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2786 holding.
  • GAMMA Investing first reported a position in Intellia Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's Intellia Therapeutics position peaked at $59.2K in Q2 2024.
  • 6 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.